^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Protein complex 1 inhibitor

    Related drugs:
    2ms
    A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • albumin-bound paclitaxel • lixumistat (IM156)
    7ms
    A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. (clinicaltrials.gov)
    P1, N=25, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2025 --> Feb 2027 | Trial primary completion date: Jan 2025 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • lixumistat (IM156)
    2years
    A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. (clinicaltrials.gov)
    P1, N=25, Recruiting, M.D. Anderson Cancer Center | Phase classification: P1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    gemcitabine • albumin-bound paclitaxel • lixumistat (IM156)